ShareValue scores for 002022.SHE: Valuation 58, Quality 25, Growth 41, Health 35.
002022.SHESZSE
Shanghai Kehua Bio-Engineering Co Ltd
CN¥5.29
(+1.34%)
002022.SHESZSE
Shanghai Kehua Bio-Engineering Co Ltd
Verdicts
Verdicts
Fundamental Rating
Value Trap Risk
Expected Return
Rating
Trap Risk
Return
Company Details
Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of reagents and instruments and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated comprehensive solutions for nucleic acid blood screening. It also provides automatic modular and clinical chemistry analyzers and clinical chemistry reagents test menu; automatic chemiluminescence immunoassay analyzers and CLIA reagents test menu; automatic ELISA microplate readers, ELISA microplate washers, and enzyme-linked immunoassay reagents; and diagnostics kit for HIV and SARS-CoV-2 IgM/IgG antibody, HIV I/II Ab rapid tests, diagnostic kit for Hepatitis B surface antigen and Hepatitis C virus antibody, and diagnostic kit for antibody to T. Palladium. In addition, the company offers molecular diagnostics solutions, including fully automated nucleic acid blood screening laboratory solution and nucleic acid testing and detection kits; automatic multifunctional veterinary analyzer; and mass spectrometry. It exports its products. Further, it provides instrument products, including biochemical diagnostics, immunological diagnostics, molecular diagnostics, point-of-care testing (POCT), and mass spectrometry, advancing towards automation, digitization, and intelligence. The company serves healthcare institutions, blood centers, disease control and prevention centers, and research organizations. Its products are used in clinical diagnostics, blood screening, public health, food safety, and scientific research applications. The company was founded in 1981 and is headquartered in Shanghai, China.